During Wednesday’s Current trade, Shares of The Medicines Company (NASDAQ:MDCO), gain 0.97% to $41.60.
The Medicines Company (MDCO) declared its financial results for the second quarter and first half of 2015.
Second-Quarter 2015 Financial Summary
Worldwide net revenue was $90.5 million for the second quarter of 2015 contrast to $183.8 million in the second quarter of 2014. Worldwide Angiomax®/Angiox® (bivalirudin) revenue was $65.6 million in the second quarter of 2015 contrast to $163.1 million in the second quarter of 2014, with revenue in the United States decreasing to $60.5 million in the second quarter of 2015 from $152.2 million in the second quarter of 2014. Recothrom®, Thrombin topical (Recombinant) sales were $15.9 million contrast to $16.3 million in the second quarter of 2014. Other products counting Cleviprex® (clevidipine), Argatroban for Injection, 50 mg per mL, Minocin® (minocycline) for injection, Orbactiv® (oritavancin) and PreveLeakTM Surgical Sealant recorded sales of $9.0 million during second quarter of 2015 contrast to $4.4 million in the second quarter of 2014. Not taking into account Angiomax, the company recorded 20% higher net revenue during the second quarter of 2015 contrast to the second quarter of 2014.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
Shares of FuelCell Energy Inc (NASDAQ:FCEL), inclined 2.93% to $0.929, during its current trading session.
FuelCell Energy, Inc. (FCEL), a global leader in the design, manufacture, operation and service of ultra‐clean, efficient and reliable fuel cell power plants, recently declared the appointment of two new members to the Company’s Board of Directors, counting Paul F. Browning, former President and Chief Executive Officer, Irving Oil Company Limited and Matthew F. Hilzinger, Executive Vice President and Chief Financial Officer, USG Corporation. These additions to the FuelCell Energy Board of Directors enhance the total number of members to ten.
FuelCell Energy, Inc., together its auxiliaries, designs, manufactures, sells, installs, operates, and services stationary fuel cell power plants for distributed power generation. The company is also involved in the development, design, production, and sale of fuel cell products under the Direct FuelCell name. Its power plants electrochemically produce electricity and heat using various fuels, counting natural gas, methanol, diesel, biogas, coal gas, coal mine methane, and propane.
CIT Group Inc. (NYSE:CIT), during its Wednesday’s current trading session gained 1.18% to $42.92.
CIT Group Inc. (CIT) cit.com, a global leader in transportation finance, recently declared that CIT Maritime Finance offered a $61 million senior secured credit facility to Advantage Tankers, LLC, a Marshall Islands-based holding company established to acquire an operating fleet of crude tankers. The facility supports the acquisition of two Suezmax crude tankers which are employed on long-term charters to a multinational oil company. Financing was offered by CIT Bank, N.A., the principal bank partner of CIT. Terms of the transaction were not revealed.
CIT Group Inc. operates as the holding company for CIT bank that provides commercial financing and leasing products; and a suite of savings options in the United States. Its Transportation & International Finance segment offers leasing and financing solutions to operators and suppliers in the aviation and railcar industries.
Finally, Five Below Inc (NASDAQ:FIVE), decreased -1.98%, to $33.68.
Five Below, Inc. (FIVE) declared financial results for the thirteen and twenty-six weeks ended August 1, 2015.
For the thirteen weeks ended August 1, 2015:
- Net sales raised by 19.5% to $182.2 million from $152.5 million in the second quarter of fiscal 2014; comparable store sales raised by 3.0%.
- Operating income reduced to $11.6 million from $13.3 million in the second quarter of fiscal 2014 driven by the predictable deleverage associated with the new distribution center, leadership investments and a shift in marketing spend.
- The Company opened 32 new stores and ended the quarter with 417 stores in 26 states. This represents an enhance in stores of 18.1% from the end of the second quarter of fiscal 2014.
- U.S. generally accepted accounting principles, or GAAP, net income was $7.1 million contrast to $8.3 million in the second quarter of fiscal 2014.
- GAAP diluted income per common share was $0.13 contrast to $0.15 per share in the second quarter of fiscal 2014.
Five Below, Inc. operates as a specialty value retailer in the United States. It offers accessories, counting novelty socks, sunglasses, jewelry, scarves, gloves, hair accessories, athletic tops and bottoms, and t-shirts, in addition to beauty products comprising nail polish, lip gloss, fragrance, and branded cosmetics; and items used to complete and personalize living space, counting glitter lamps, posters, frames, fleece blankets, pillows, candles, incense and related items, and storage options for the customer’s room and locker.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
